Literature DB >> 31558683

APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore.

Shrijal S Shah1, Herbert Lannon1, Leny Dias1, Jia-Yue Zhang1, Seth L Alper1, Martin R Pollak1, David J Friedman2.   

Abstract

BACKGROUND: Genetic Variants in Apolipoprotein L1 (APOL1) are associated with large increases in CKD rates among African Americans. Experiments in cell and mouse models suggest that these risk-related polymorphisms are toxic gain-of-function variants that cause kidney dysfunction, following a recessive mode of inheritance. Recent data in trypanosomes and in human cells indicate that such variants may cause toxicity through their effects on mitochondria.
METHODS: To examine the molecular mechanisms underlying APOL1 risk variant-induced mitochondrial dysfunction, we generated tetracycline-inducible HEK293 T-REx cells stably expressing the APOL1 nonrisk G0 variant or APOL1 risk variants. Using these cells, we mapped the molecular pathway from mitochondrial import of APOL1 protein to APOL1-induced cell death with small interfering RNA knockdowns, pharmacologic inhibitors, blue native PAGE, mass spectrometry, and assessment of mitochondrial permeability transition pore function.
RESULTS: We found that the APOL1 G0 and risk variant proteins shared the same import pathway into the mitochondrial matrix. Once inside, G0 remained monomeric, whereas risk variant proteins were prone to forming higher-order oligomers. Both nonrisk G0 and risk variant proteins bound components of the mitochondrial permeability transition pore, but only risk variant proteins activated pore opening. Blocking mitochondrial import of APOL1 risk variants largely eliminated oligomer formation and also rescued toxicity.
CONCLUSIONS: Our study illuminates important differences in the molecular behavior of APOL1 nonrisk and risk variants, and our observations suggest a mechanism that may explain the very different functional effects of these variants, despite the lack of consistently observed differences in trafficking patterns, intracellular localization, or binding partners. Variant-dependent differences in oligomerization pattern may underlie APOL1's recessive, gain-of-function biology.
Copyright © 2019 by the American Society of Nephrology.

Entities:  

Keywords:  APOL1; chronic kidney disease; focal segmental glomerulosclerosis; genetic renal disease; mitochondria

Mesh:

Substances:

Year:  2019        PMID: 31558683      PMCID: PMC6900802          DOI: 10.1681/ASN.2019020114

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  53 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.

Authors:  John F O'Toole; William Schilling; Diana Kunze; Sethu M Madhavan; Martha Konieczkowski; Yaping Gu; Liping Luo; Zhenzhen Wu; Leslie A Bruggeman; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 10.121

Review 3.  Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury.

Authors:  A P Halestrap; C P Connern; E J Griffiths; P M Kerr
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

4.  APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.

Authors:  Yulong Fu; Jun-Yi Zhu; Adam Richman; Yi Zhang; Xuefang Xie; Jharna R Das; Jinliang Li; Patricio E Ray; Zhe Han
Journal:  J Am Soc Nephrol       Date:  2016-11-18       Impact factor: 10.121

5.  APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.

Authors:  Etty Kruzel-Davila; Revital Shemer; Ayala Ofir; Ira Bavli-Kertselli; Ilona Darlyuk-Saadon; Pazit Oren-Giladi; Walter G Wasser; Daniella Magen; Eid Zaknoun; Maya Schuldiner; Adi Salzberg; Daniel Kornitzer; Zvonimir Marelja; Matias Simons; Karl Skorecki
Journal:  J Am Soc Nephrol       Date:  2016-11-18       Impact factor: 10.121

6.  Functional characterization of UCP1 in mammalian HEK293 cells excludes mitochondrial uncoupling artefacts and reveals no contribution to basal proton leak.

Authors:  Martin Jastroch; Verena Hirschberg; Martin Klingenspor
Journal:  Biochim Biophys Acta       Date:  2012-06-04

7.  APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction.

Authors:  Lijun Ma; Jeff W Chou; James A Snipes; Manish S Bharadwaj; Ann L Craddock; Dongmei Cheng; Allison Weckerle; Snezana Petrovic; Pamela J Hicks; Ashok K Hemal; Gregory A Hawkins; Lance D Miller; Anthony J A Molina; Carl D Langefeld; Mariana Murea; John S Parks; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 10.121

8.  Mechanism of Trypanosoma brucei gambiense resistance to human serum.

Authors:  Pierrick Uzureau; Sophie Uzureau; Laurence Lecordier; Frédéric Fontaine; Patricia Tebabi; Fabrice Homblé; Axelle Grélard; Vanessa Zhendre; Derek P Nolan; Laurence Lins; Jean-Marc Crowet; Annette Pays; Cécile Felu; Philippe Poelvoorde; Benoit Vanhollebeke; Soren K Moestrup; Jeppe Lyngsø; Jan Skov Pedersen; Jeremy C Mottram; Erick J Dufourc; David Pérez-Morga; Etienne Pays
Journal:  Nature       Date:  2013-08-21       Impact factor: 49.962

9.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

10.  APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis.

Authors:  Duncan B Johnstone; Vijay Shegokar; Deepak Nihalani; Yogendra Singh Rathore; Leena Mallik; Vasant Zare; H Omer Ikizler; Rajaram Powar; Lawrence B Holzman
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more
  29 in total

1.  GWAS in Mice Maps Susceptibility to HIV-Associated Nephropathy to the Ssbp2 Locus.

Authors:  Nicholas J Steers; Yask Gupta; Vivette D D'Agati; Tze Y Lim; Natalia DeMaria; Anna Mo; Judy Liang; Kelsey O Stevens; Dina F Ahram; Wan Yee Lam; Mihai Gagea; Lalitha Nagarajan; Simone Sanna-Cherchi; Ali G Gharavi
Journal:  J Am Soc Nephrol       Date:  2021-12-10       Impact factor: 10.121

2.  APOL1 Risk Variants Impair Multiple Mitochondrial Pathways in a Metabolomics Analysis.

Authors:  Lijun Ma; Nicholette D Palmer; Young A Choi; Mariana Murea; James A Snipes; John S Parks; Carl D Langefeld; Barry I Freedman
Journal:  Kidney360       Date:  2020-09-30

3.  An Acidic Environment Induces APOL1-Associated Mitochondrial Fragmentation.

Authors:  DengFeng Li; James A Snipes; Mariana Murea; Anthony J A Molina; Jasmin Divers; Barry I Freedman; Lijun Ma; Snezana Petrovic
Journal:  Am J Nephrol       Date:  2020-08-31       Impact factor: 3.754

4.  Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function.

Authors:  Somenath Datta; Rama Kataria; Jia-Yue Zhang; Savannah Moore; Kaitlyn Petitpas; Adam Mohamed; Nathan Zahler; Martin R Pollak; Opeyemi A Olabisi
Journal:  J Am Soc Nephrol       Date:  2020-07-16       Impact factor: 10.121

5.  Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes.

Authors:  Suzie J Scales; Nidhi Gupta; Ann M De Mazière; George Posthuma; Cecilia P Chiu; Andrew A Pierce; Kathy Hötzel; Jianhua Tao; Oded Foreman; Georgios Koukos; Francesca Oltrabella; Judith Klumperman; WeiYu Lin; Andrew S Peterson
Journal:  J Am Soc Nephrol       Date:  2020-08-06       Impact factor: 10.121

6.  APOL1 risk variants induce opening of the mitochondrial permeability transition pore.

Authors:  Ellen F Carney
Journal:  Nat Rev Nephrol       Date:  2019-12       Impact factor: 28.314

Review 7.  APOL1 Nephropathy: From Genetics to Clinical Applications.

Authors:  David J Friedman; Martin R Pollak
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-02       Impact factor: 8.237

8.  APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis.

Authors:  Jarcy Zee; Michelle T McNulty; Jeffrey B Hodgin; Olga Zhdanova; Sangeeta Hingorani; Jonathan Ashley Jefferson; Keisha L Gibson; Howard Trachtman; Alessia Fornoni; Katherine M Dell; Heather N Reich; Serena Bagnasco; Larry A Greenbaum; Richard A Lafayette; Debbie S Gipson; Elizabeth Brown; Matthias Kretzler; Gerald Appel; Kamalanathan K Sambandam; Katherine R Tuttle; Dhruti Chen; Meredith A Atkinson; Marie C Hogan; Frederick J Kaskel; Kevin E Meyers; John O'Toole; Tarak Srivastava; Christine B Sethna; Michelle A Hladunewich; J J Lin; Cynthia C Nast; Vimal K Derebail; Jiten Patel; Suzanne Vento; Lawrence B Holzman; Ambarish M Athavale; Sharon G Adler; Kevin V Lemley; John C Lieske; Jonathan J Hogan; Crystal A Gadegbeku; Fernando C Fervenza; Chia-Shi Wang; Raed Bou Matar; Pamela Singer; Jeffrey B Kopp; Laura Barisoni; Matthew G Sampson
Journal:  Pediatr Nephrol       Date:  2021-03-01       Impact factor: 3.714

9.  APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.

Authors:  Mengyuan Ge; Judith Molina; G Michelle Ducasa; Shamroop K Mallela; Javier Varona Santos; Alla Mitrofanova; Jin-Ju Kim; Xiaochen Liu; Alexis Sloan; Armando J Mendez; Santanu Banerjee; Shaoyi Liu; Hazel H Szeto; Myung K Shin; Maarten Hoek; Jeffrey B Kopp; Flavia Fontanesi; Sandra Merscher; Alessia Fornoni
Journal:  Hum Mol Genet       Date:  2021-04-26       Impact factor: 6.150

Review 10.  The Use of Genomics to Drive Kidney Disease Drug Discovery and Development.

Authors:  Dermot F Reilly; Matthew D Breyer
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-19       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.